Anthera's cystic fibrosis drug fails late-stage study, shares tank

(Reuters) - Anthera Pharmaceuticals Inc said on Tuesday that its drug to treat certain cystic fibrosis patients failed a late-stage study, sending the company's shares tumbling nearly 70 percent in after-hours trading.